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Background: We describe a multistep model of cancer genetic counselling designed to promote awareness,
and disease surveillance and preventive measures for hereditary and familial breast and ovarian cancer.
Patients and methods: Step T0 of the model entails information giving; this is followed by pedigree analysis
and risk estimation (T1), risk communication and genetic testing (T2), and genetic test result communication
(T3). User consent was required to proceed from one step to the next. Surveillance and preventive measures are
proposed to at-risk users. Of the 311 subjects who requested cancer genetic counselling, consent data to each
counselling step were available for 295: 93 were disease-free, 187 had breast cancer, 12 had ovarian cancer and
three had breast plus ovarian cancer.
Results: Consent was high at T0 (98.39%), T1 (96.40%) and T2 (99.65%). Consent decreased at the crucial
points of counselling: T2 (87.71%) and T3 [genetic test result communication (85.08%), and extension of coun-
selling to and testing of relatives (65.36%)].
Conclusions: The model fosters the user’s knowledge about cancer and favours identification of at-risk sub-
jects. Furthermore, by promoting awareness about genetic testing and surveillance measures, the algorithm ena-
bles users to make a fully informed choice of action in case of predisposing or familial cancer risk.
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Introduction
It has been estimated that ∼70% of all primary breast cancers are
sporadic forms, between 15% and 20% are familial forms and the
remaining 5–10% are hereditary [1–4]. In this context, identifica-
tion of the BRCA1 and BRCA2 susceptibility genes [5, 6] provided
a molecular basis for genetic testing. This, together with increased
breast cancer awareness in the general population, has increased
the demand for identification of the hereditary risk, mainly as
regards identification of the susceptibility gene. Moreover, the
identification of familial risk favours the use of surveillance
measures also in relatives at moderate risk of cancer. Conse-
quently, when one of these forms of hereditary or familial breast
and/or ovarian cancer is suspected in clinical practice, the general
practitioner should address the patient to an oncological centre
specialising in cancer genetic counselling for risk identification,
definition and management [7–11].
Genetic counselling, defined by the American Society of Human
Genetics as ‘a communication process which deals with the human
problems associated with the occurrence or risk of occurrence of a
genetic disorder in a family’ (our italics), involves one or more
appropriately trained persons to help the affected individual or
family [9, 10, 12, 13]. Genetic counselling in the oncological
setting (cancer genetic counselling) should also provide sufficient
information to enable the user to make a fully informed choice of
action, particularly as regards prevention, in case of identification
of a mutation or of a familial cancer risk [11].
In Italy, where health care is mainly a public service, cancer
genetic counselling is a relatively new concept and is almost
invariably offered within the framework of research projects [14].
The onset of cancer genetic counselling, which at first focused on
genetic testing, coincided with a change in the physician/patient
relationship as the Italian public became more aware of improve-
ments in cancer treatment, in palliative care and in prevention. In
recognition of this new scenario, the Ministry of Research funded
a research project entitled the Development of a National Network
for the Study of Hereditary Breast Cancer [15]. Five clinically
oriented centres of this network (representing northern, central
and southern areas of the country) are implementing a multistep
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model of cancer genetic counselling based on the experience
initiated and promoted by the Naples Unit.
Given the highly technical expertise required for cancer
management, and the need to provide updated information about
diagnostic methods and treatment options, the oncologist seems to
be the most appropriate professional figure for the role of counsel-
lor. In fact, the oncologist is able to play a comprehensive role in
assessing familial cancer risks and in the counselling process start-
ing from risk identification to risk management [16]. Considering
the multidisciplinary nature of cancer genetic counselling, our
model also foresees close links with the psychologist, geneticist,
radiologist, gynaecologist and surgeon during the patient’s educa-
tional process and as required in the various counselling steps.
The defining features of the model described herein are: (a) it is
an educational model; (b) it aims at promoting awareness; and (c)
it aims at promoting prevention and surveillance measures in sub-
jects who have been identified as being at hereditary or familial
risk. Here we describe this model and report the ‘consent’ to each
counselling step obtained in 311 subjects.
Patients and methods
Subjects who requested counselling were referred by their physician or came
spontaneously to the Screening and Follow-up for Hereditary and Familial
Tumours Unit (Azienda Ospedaliera Universitaria ‘Federico II’, Naples), the
Centre for the Study of Familial Breast and Ovarian Tumours (Modena Poly-
clinic), the Medical Oncology Division (University of L’Aquila), and the
Regional Reference Centre for Genetic Counselling and High Technology
Therapies in Medical Oncology (‘Mater Domini’ Polyclinic, Catanzaro),
between 1999 and 2001. The Ethics Committees of the participating units
approved the counselling procedures. Each participating centre adhered to the
counselling model proposed by the Naples unit.
Counselling was addressed to: (a) cancer-affected subjects with a personal
history suggesting genetic risk (e.g. early onset breast cancer, male breast
cancer, breast and ovarian cancer in the same subject and multiple cancers
besides breast or ovarian cancer in the same subject), or with a family history
of cancer; and (b) disease-free subjects belonging to families with cancer
clustering.
The multistep counselling model
The counselling teams included an oncologist/counsellor, psychologist,
geneticist, radiologist, gynaecologist and surgeon, except in the Catanzaro unit
where there was a psychiatrist instead of a psychologist. The model was
designed to promote awareness using a multistep approach in order to allow
users to assimilate fully the information given, to adapt to the new reality and
to become fully aware of their condition and all its implications. Sessions with
a psychologist are structured within the model, and subjects may request a
session with the psychologist whenever they want information or need sup-
port. Adequate time is set aside for each counselling step, and each subject
decides when he/she is ready for the next step. Every effort is made to protect
the user’s privacy. Easy-to-understand language adapted to each subject is
used. The communicative modalities are modelled according to the affected or
disease-free condition of the proband and to his/her cultural profile. Interaction
between users and the oncologist is informal and respects the communication
process typical of the clinical setting.
The steps of the model are shown in Figure 1 and in Table 1. At step T0, the
aims and organisation of cancer genetic counselling are explained by the
Table 1. Methodological scheme at the various steps of the model and the professionals involved in each step
Step Description Professionals involved
T0 Providing information Information/education about sporadic, familial and hereditary 
breast cancers.
Oncologist counsellor; psychologist 
(psychiatrist at the Catanzaro unit)
Information about risk assessment procedures.
Information/education about preventive strategies, lifestyle 
implications and health-promoting behaviour.
Collection of personal history, histological report.
T1 Pedigree construction Pedigree construction for at least three generations. Oncologist counsellor
Risk estimation Analysis of pedigree acquired. The risk profile is defined as 
individual, familial and inherited (Claus, Modena and 
Frank models).
Oncologist counsellor; geneticist 
(when requested)
T2 Risk communication Communication about individual and/or familial and/or 
inherited risk.
Oncologist counsellor; psychologist 
(psychiatrist at the Catanzaro unit)
Communication about the implication of the risk 
estimation for the user and for the user’s relatives.
Genetic testing considered Genetic test offered in case of suspected inherited risk.
Discussion about advantages and limits of genetic testing.
T3 Genetic test result communication Communication of the results and discussion about 
implications.
Oncologist counsellor; psychologist 
(psychiatrist at the Catanzaro unit)
Genetic results disclosure to relatives The proband informs his/her relatives about genetic test 
 results and informs them about counselling.
Counselling for relatives Relatives interested in counselling contact the unit for an 
appointment.
Oncologist counsellor; psychologist 
(psychiatrist at the Catanzaro unit)
Surveillance Surveillance measures modelled on different levels of risk. 
Discussion of preventive measures available, including 
chemoprevention and/or prophylactic surgery.
Oncologist; surgeon; gynaecologist; 
radiologist
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oncologist counsellor, and the user’s motivations and expectations with regard
to counselling are elicited. In this information-giving process the subject
learns about the hereditary, familial and sporadic forms of breast cancer, and
about the methods available to identify the risk of developing these forms of
cancer (i.e. pedigree construction and analysis, personal history collection and
susceptibility gene testing) [17–21]. The counsellor then discusses the impli-
cations of cancer risk in general terms, and the strategies available for risk
management [20], i.e. surveillance [22–24] and prevention [25–29, 30]. Dur-
ing counselling, the user is repeatedly encouraged to ask questions and seek
explanations; the user’s responses also allow the counsellor to verify the user’s
understanding. Lastly, users are instructed to collect information about their
family in preparation for step T1 (pedigree construction and risk estimation).
After information-giving by the counsellor, subjects have a session with a
psychologist to define, by way of a semi-structured interview, their cognitive
level and the presence or not of psychological distress, evaluated by self-
administered questionnaires. A low cognitive level and psychological distress
preclude continuation of counselling. The psychologist becomes familiar with
the subject’s medical condition, and explores his/her socio-cultural back-
ground, relationship with the medical team, family members and others,
personality profile and ability to adapt to changing situations.
At T1 (Figure 1 and Table 1), the proband is required to give written
informed consent (IC) to allow the counsellor to acquire information about the
family and, eventually, to disclose the results of pedigree analysis to other
family members should they request counselling in the future. Information
about the subject’s ethnic background is recorded. The proband’s family
history going back at least three generations (maternal and paternal), is
collected. The diagnosis is verified from the histological notes of the affected
proband and his/her family. Each pedigree is assigned a code, which is used
throughout the counselling process to guarantee privacy [31].
Risk is established according to Frank et al. [18], whereby the a priori risk
of being a carrier of the susceptibility genes BRCA1 and/or BRCA2 is calcu-
lated. Risk estimation is also determined according to the criteria of Modena
University [17] considering breast or ovarian cancer clustering within the
family and within generations, the degree of relationship (first and second
degree), vertical transmission, skipping a generation in case of interposition
of a male due to incomplete BRCA1 and/or BRCA2 penetrance, mono or
bilateral tumour and onset age of cancer, breast and ovarian cancer in the same
subject, and multiple cancers other than breast or ovarian in the same subject.
Pedigree analysis was performed by the oncologist and discussed with the
geneticist in the more complex cases, in uncertain cases and when the pedigree
did not contain a known cancer syndrome. At T2, the counsellor informs the
user about the presence or not of a hereditary or familial risk, or, in the case of
a disease-free proband, about an individual risk exceeding that found in the
general population. If a hereditary risk is identified, the advantages and limits
of genetic testing in defining the risk are illustrated and discussed. The user is
encouraged to ask questions to ensure that the information given has been fully
understood. The genetic test notwithstanding, the counsellor explains surveil-
lance and prevention measures for the proband and disease-free relatives who
could be at an increased risk with respect to the general population. Subjects
who are contemplating a genetic test have another session with the psycholo-
gist in order to clarify further the psychological aspects related to genetic test-
ing. Users then return to counselling and give written informed consent to
blood withdrawal for BRCA1/BRCA2 gene analysis. Gene analysis was
performed at each unit by molecular biologists with whom the counsellor
discussed the test results. The network laboratories use a standardised pro-
cedure and periodically verify testing proficiency. The costs of genetic testing
are covered, at present, by an MIUR grant. Only the affected proband or, in the
case of a disease-free proband, the youngest affected family member, has
access to gene testing. As required by Italian guidelines, unaffected probands
from families with no living affected relatives were not offered genetic testing
[32].
When the test result becomes available, the user returns to counselling and
is again required to give written consent to test result disclosure, and eventu-
ally to disclosure to relatives. Thus, if a relative requests counselling, the coun-
sellor is free to use the pedigree information previously obtained for this
family. At this time (T3), the counsellor explains the test results (positive or
negative), taking care that the user understands all aspects and implications of
the result with respect to relatives and progeny. The counsellor also explains
the advantages of a positive test (i.e. preventive measures can be scheduled)
and disadvantages of a negative result in cases of suspected hereditary risk (i.e.
possible involvement of an unknown susceptibility gene) [33]. In the case of a
positive test, the counsellor discusses with the gene carrier the possibility that
first-degree disease-free relatives undergo the genetic test. Importantly, the
user is instructed to vehicle the suggestions concerning surveillance to rela-
tives at an increased risk with respect to the general population. The user also
receives a written report that includes the test results, the procedure used for
Figure 1. The multistep cancer genetic counselling model. IC, informed consent.
 at U
niversitàdegli Studi di M
odenae Reggio Em







the test, and an explanation of the significance of the test result, together with a
copy of the pedigree. The risk information collected in the onco-genetic clinic
is integrated into the medical management of the patient by the multi-
disciplinary counselling team. The user is also advised to contact a clinical
oncological outpatients unit of the Network or a local oncological unit [15]. If
a patient requests in writing, a report is sent to the general practitioner who
referred the subject to counselling. The results of genetic testing are recorded
on a separate chart that is kept in the Family Cancer Genetics Office.
The oncologist consults the gynaecologist, surgeon and radiologist as
required to clarify aspects related to counselling. The proband decides whether
or not to inform relatives that they belong to an at-risk family or to a BRCA1/
BRCA2-carrying family, about taking surveillance measures and the pos-
sibility of genetic testing. The relatives so informed can request counselling
and start the counselling cycle from T0. In such cases the contents of each
counselling step are adapted to the user’s level of information and to his/her
expectations.
At the end of each step, the proband is given ample opportunity to discuss
any questions or problems at length in order to clarify all aspects of their con-
dition. In this regard, the inter-step interval must be sufficient so as to allow
users to elaborate the contents of the previous step so that they can express a
truly ‘aware’ consent, and not just ‘informed’ consent, to the various steps and
actions selected during counselling. Consequently, the proband decides when
he/she is ready for the subsequent counselling session based on appointments
offered after 1 week, 2 weeks or longer. Each time informed consent is
required, users are reminded that they have the right to rescind their decision at
any time.
Results
Cancer genetic counselling was requested by 311 subjects, 21
(6.7%) of whom were referred by their physician, 243 (78.2%)
were recruited from the clinical service of the participating depart-
ments, and the remaining 47 (15.1%) requested counselling spon-
taneously.
Of the 311 subjects who requested cancer genetic counselling in
the five participating centres of the National Network for the Study
of Hereditary Breast Cancer, 306 underwent step T0 (Figure 1).
After information-giving by the oncologist, these subjects under-
went an interview with a psychologist. Eleven subjects did not
return to counselling or refused the psychologist interview or
showed low motivation for counselling after referral by their
physicians. The remaining 295 subjects (all Caucasian) returned
to counselling and gave their informed consent for pedigree con-
struction and risk estimation (step T1). Of these, 93 subjects were
disease-free, 187 had primary breast cancer, 12 primary ovarian
cancer and three primary breast cancer (BC) and ovarian cancer
(OC). Patients were evaluated by counsellors at different stages of
their oncological history: 146 (72.2%) during follow-up and 56
(27.8%) during advanced disease. Disease-free subjects were
referred to counselling for various reasons: 54 (58.2%) for high
familial clustering (at least three cases of BC and/or OC), 22
(23.6%) had at least one first-degree relative affected by BC and/
or OC, and 17 (18.2%) with early onset BC or male breast cancer
in the family. The age at diagnosis of breast cancer was <35 years
in 28 subjects and ≥35 years in the remaining 159 breast cancer
subjects (overall age range 27–80 years; median age 47 years).
The age range of ovarian cancer patients was 29–63 years (median
age 40 years). Sixty-six disease-free subjects were premenopausal
and 23 postmenopausal, and four of the disease-free subjects were
male.
Based on pedigree analysis, and personal history data in the
case of disease-free individuals, we used the criteria of Modena
University [17] and the Frank model [18] to divide the families
into risk categories based on the hereditary and familial risk in all
subjects.
A total of 292 (99.65%) subjects attended the T2 counselling
session (risk communication). Of the three subjects who did not
attend this session, one died and two decided not to proceed. At
T2, the oncologist communicates the results of the pedigree
analysis. In case of hereditary or familial risk or when a disease-
free subject had a risk greater than that of the general population,
information about surveillance and prevention measures was
given to the subjects undergoing counselling and to their relatives
if requested. Of these 292 subjects, 140 belonged to genetic at-risk
families and were given details about identifying the risk by
genetic testing.
At a subsequent appointment, 122 (87.71%) subjects from
at-risk families gave written informed consent to blood with-
drawal for genetic testing. Of these, 106 subjects were probands
with primary breast cancer, eight had primary ovarian cancer, four
had primary breast plus ovarian cancer, and four were relatives of
disease-free probands who had participated in counselling from
T0. Eighteen subjects decided not to undergo genetic testing.
These subjects were encouraged to take disease surveillance and
prevention measures. Of the 114 subjects informed that their test
result was ready, 97 decided to learn the result (T3). As with the
18 subjects who did not take the genetic test, the 17 subjects who
preferred not to know the result of their genetic test were informed
of the importance of taking surveillance and prevention measures,
and advised to contact a clinical oncological outpatients unit of the
Network or their local oncological unit. They were also advised
that they could request their test result at any time in the future
should they change their mind.
Fifty-nine disease-free subjects, who were relatives of probands
with a positive test, were informed by the proband that they
belonged to an at-risk family. Thirty-four of these relatives
requested counselling and underwent counselling starting at T0
(Figure 1); in these cases the contents of each step were modified
depending on the user’s level of information and on his/her
expectations. Twenty-five of the 59 disease-free subjects did not
undergo counselling, even though they had been informed by the
proband that they belonged to an at-risk family.
Consent to the counselling model differed among the various
steps of the model (Figure 2). The interstep interval was usually
around 1–2 weeks. At T0, T1 and T2 (as regards risk communi-
cation), the percentage of consent was very high, with only a few
cases of non-adhesion due to missed appointments (T0), a change
of mind about pedigree construction and risk estimation (T1), and
a change of mind about risk communication (T2). In contrast, the
per cent of consent decreased in steps T2 (genetic testing) and T3.
The drop-outs were: (a) subjects who, although they belonged to a
family at genetic risk, did not undergo genetic testing at T2 (sub-
jects who died and subjects who changed their mind about genetic
testing); (b) subjects who underwent blood sampling for genetic
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testing but decided not to know the genetic test result, or who died
(T3); and (c) subjects who, although they were informed by the
proband that they belonged to an at-risk family, decided not to
undergo genetic counselling (subjects who opted for surveillance
measures only).
Discussion
Here we report the experience of five centres of the Italian Net-
work for the Study of Hereditary Breast Cancer in applying a new
model of cancer genetic counselling. This counselling service was
available to cancer patients and to healthy subjects with a family
history of cancer [15].
There is now general consensus that primary breast cancer
exists in distinct forms: hereditary, familial and sporadic. The
development of cancer genetics has led to a need for medical
services, including cancer genetic counselling, for affected
individuals and their families. In this regard and considering the
complexities of cancer genetic counselling and the time required
for the process, the oncologist involved in general oncology prac-
tice would be well advised to refer patients to an established onco-
genetic service, if available [12, 25]. The oncologist counsellor is
able to cover the whole spectrum of cancer genetic counselling,
from verification of cases, risk assessment, genetic counselling
and testing, and follow-up of at-risk subjects. The oncologist can
refer users to other professional figures that can address the
psychosocial needs of family members or that are involved in the
educational and clinical management process.
It is difficult to compare our model of genetic counselling with
others being applied nationally and internationally, particularly
because, to our knowledge, data on adherence to the various
models are lacking. The multistep counselling model described
herein is based on the concept that information-giving is a
dynamic process occurring over time because the individual needs
time to assimilate new information and to adapt to a new reality. In
particular, users must come to terms with the fear evoked by
cancer, loss of functioning, and the possibility of transmitting
cancer to progeny. Because the proband must give written
informed consent at each crucial step of cancer genetic counsel-
ling, and because he/she has ample time to assimilate the contents
of the previous counselling step, consent is not merely informed
but is an aware consent. With the awareness resulting from this
step-by-step counselling, users probably have a correct perception
of their risk.
An interesting bi-model profile emerged from the consent
results (Figure 2). In fact, sessions from T0 to T2, which cover
information-giving and risk communication, were characterised
by a high level of consent, after which consent decreased. Interest-
ingly, the crucial point occurred when the question of genetic test-
ing became a reality, i.e. when the user must decide whether or not
to take the test, and when it comes to deciding whether or not to
know the test result. Consent decreased even further when the user
had to decide whether or not to inform relatives that they belonged
to a family bearing a predisposing cancer mutation. These results
demonstrate that the users felt completely free to reconsider their
decision at any time during the counselling process.
The model aims at identifying at-risk subjects (i.e. defining the
risk as hereditary, familial or individual when the subject referred
to counselling is disease-free), and directing subjects to surveil-
lance [17–19] and prevention [25–29]. In fact, immediately after
pedigree analysis, subjects are referred to surveillance and pre-
vention as necessary regardless of consent or not to subsequent
Figure 2. Consent to the multistep cancer genetic counselling model. The percentage of consent is calculated on the basis of the number of users scheduled/
attending the counselling session.
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counselling sessions. In the multistep model, through information-
giving and the implication-counselling discussion, users probably
become more aware of their risk, and are thus more likely to
adhere to surveillance and prevention regimes. In fact, users were
informed that effective preventive measures can significantly
reduce the risk of breast and/or ovarian cancer in individuals at
increased risk, and that surveillance modalities favour the early
diagnosis of cancer so that the vast majority of patients diagnosed
with early-stage breast cancer die from causes other than cancer
[29]. This is important also in the light of the recent widespread
advertising campaign for genetic testing in the USA, which may
be open to criticism on the grounds that it is a predictive test for a
condition for which there is no cure, namely predisposition to
cancer. Our educational model of cancer genetic counselling is
aimed not only at genetic testing, but also at surveillance and pre-
ventive measures not only in the proband but also in relatives at
risk of both hereditary and familial forms of cancer, irrespective of
the identification of the predisposing mutation in the family.
In accordance with the recent American Society of Clinical
Oncology Policy Statement Update: Genetic Testing for Cancer
Susceptibility [12], our model is based on the fact that ‘many of
the management decisions surrounding the care of cancer patients
with inherited cancer-predisposing mutations require a level of
clinical expertise that is most likely within the purview of the
oncology practitioner or a multidisciplinary team of specialists.’
Our model also incorporates other main features recommended by
ASCO: educational opportunities, requirement for informed con-
sent, and integration of cancer risk assessment and management
into oncology practice and prevention. The costs of this type of
cancer genetic counselling will probably be offset by a decrease in
cancer patients because more patients and relatives are taking
early surveillance and preventive measures.
Given the high rate of consent throughout the counselling pro-
cess, we believe that this multistep model might represent one of
the strategies for the management of subjects at risk of hereditary
and familial breast and/or ovarian cancers.
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